AZD-5462

心力衰竭，这个沉重的医学名词，对于无数患者及其家庭而言，意味着持续的呼吸困难、水肿、乏力，以及对生命质量的严峻挑战。据统计，全球有数千万人深受心力衰竭困扰，其高致残率和致死率使其成为威胁人类健康的重要疾病之一。尽管医学界在心衰治疗领域已取得显著进展，但现有治疗手段仍存在局限性，无法彻底逆转疾病进程，这使得新药研发成为刻不容缓的医学前沿。松弛素：一个备受期待的新靶点在寻找心力衰竭治疗新策略的漫漫征途中，一种名为“松弛素”的内源性激素逐渐进入了科研人员的视野。松弛素并非一个陌生的概念，它在人体内扮演着多重生理角色，尤其在心血管系统中展现出独特的潜力。松弛素的独特作用机制 扩血管作用：松弛素能够促使血管扩张，降低外周血管阻力，从而减轻心脏的负荷，改善心肌供血。 抗炎作用：心力衰竭的发生发展往往伴随着慢性炎症反应。松弛素具有抑制炎症介质释放、减轻炎症损伤的能力，有助于保护心肌细胞。 抗纤维化作用：心肌纤维化是心力衰竭恶化的重要病理基础。松弛素能够抑制成纤维细胞的增殖和胶原蛋白的沉积，从而对抗心肌纤维化，维持心肌结构和功能的完整性。正是由于这些多靶点、多层面的作用机制，松弛素被医学界寄予厚望，认为其有望成为治疗心力衰竭的潜在突破性靶点。回顾历史，对松弛素的研究并非一帆风顺。早在2013年，已有制药公司启动了重组松弛素-2肽的三期心衰临床试验，但由于各种原因，其临床转化之路充满挑战，其中一个关键症结便是早期候选药物的半衰期过短，难以在体内维持稳定的有效浓度。阿斯利康的松弛素新药研发之路面对松弛素临床应用中的瓶颈，全球领先的制药企业阿斯利康并未却步，而是以其深厚的研发实力和“侦探”般的科学精神，持续探索松弛素在心力衰竭治疗中的潜力。AZD3427的探索与挑战阿斯利康曾研发出一种长效松弛素-2类似物——AZD3427。这款药物的创新之处在于，它通过融合蛋白技术延长了松弛素的半衰期，使其在体内作用时间从数小时延长至数天，旨在克服此前研究中遇到的难题。然而，在对260名心力衰竭患者进行二期临床试验后，AZD3427的疗效表现平平，未能达到预期的突破性效果。基于严谨的科学评估，阿斯利康最终决定终止AZD3427的开发项目，这再次印证了新药研发的艰巨性与不确定性。AZD5462：口服小分子药物的新希望尽管AZD3427的研发受挫，但阿斯利康并未放弃对松弛素靶点的信心。他们将目光投向了另一个更具潜力的方向——口服小分子松弛素药物AZD5462。这款药物被誉为首个进入临床试验的、靶向松弛素生物学的口服小分子药物，其口服给药的便利性有望显著提升患者的依从性，具有更广阔的应用前景。目前，AZD5462正处于慢性心力衰竭稳定期患者的二期B临床试验阶段，预计相关数据将在2026年下半年公布。阿斯利康高管对AZD5462寄予厚望，他们强调，从以往的经验中汲取教训，深入理解生理机制，尤其是在“剂量”与“疗效”之间寻找最佳平衡点，是确保新药成功的关键。这正是科学研究的魅力所在，每一次的挫折都可能成为通往成功的垫脚石。心衰治疗的未来展望近年来，心力衰竭治疗领域可谓硕果累累。从早期的血管紧张素转换酶抑制剂（ACE抑制剂）到近年来的钠-葡萄糖协同转运蛋白2抑制剂（SGLT2抑制剂），这些突破性的药物极大地改善了心力衰竭患者的预后，为特定患者群体带来了实实在在的益处。这些成功案例不仅为新药研发树立了典范，也激励着科研人员不断探索更精准、更有效的治疗方案。新药研发之路充满挑战，但每一次的尝试都蕴含着无限机遇。阿斯利康在松弛素领域的持续投入，正是这种不懈探索精神的体现。对于广大心力衰竭患者而言，这意味着未来可能有更多、更好的治疗选择，有望提升生活质量，延长生命周期。我们期待AZD5462能够顺利完成临床试验，为心力衰竭的治疗版图增添浓墨重彩的一笔。结语心力衰竭新药的研发是医学界永恒的课题。每一次科学的进步，都凝聚着无数科研人员的智慧与汗水，也承载着患者对健康的殷切期盼。阿斯利康在松弛素药物研发上的努力，无论结果如何，都将为我们深入理解心力衰竭的病理生理机制，以及探索新的治疗策略提供宝贵的经验。作为患者，我们应保持积极心态，遵医嘱规范治疗，同时关注医学前沿进展，与医生共同探讨最适合自己的治疗方案。相信在医学科技的不断进步下，心力衰竭的治疗前景将更加光明。注：本文内容仅供科普参考，不构成专业医疗建议，如有健康问题请咨询专业医生。返回搜狐，查看更多

AstraZeneca shared news it cut AZD3427 from its pipeline alongside the removal of two other new molecular entities.\n AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates. As part of its full-year 2025 financial results (PDF), the U.K.-based Big Pharma revealed that it removed a long-acting relaxin-2 analog called AZD3427 from its pipeline, citing underwhelming efficacy in a phase 2 trial.There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s vasodilatory, anti‐inflammatory and antifibrotic effects has yet to translate into clinical success.AstraZeneca identified the short half-lives of earlier candidates as a potential cause of the failures. To fix the problem, the company created a relaxin-2 mimic fusion protein and attached a fragment to create a candidate with a half-life measured in days rather than hours. However, AstraZeneca has now stopped development of AZD3427 after completing a phase 2 trial in 260 people with heart failure.   While AZD3427 has been sunk by efficacy, the company is continuing to develop the oral relaxin drug candidate AZD5462. AstraZeneca has called (PDF) the candidate the first small molecule targeting relaxin biology to enter clinical trials. Data from a phase 2b trial of stable patients with chronic heart failure are due in the second half of 2026.During a press conference this morning, Sharon Barr, Ph.D., executive vice president of biopharmaceuticals R&D at AstraZeneca, told Fierce the company is moving forward with AZD5462 “because we think this is a potentially important molecule.”“One of the things that we have learned from competitor studies is that dosing matters,” Barr continued. “You really have to find that perfect space between efficacy and congestion, and we think we\'ve put in the hard yards to really understand the posology there, and we\'re moving forward with our existing program.”AstraZeneca CEO Pascal Soriot also told Fierce during the call that work on the relaxin program is a case study of “what is so exciting in this industry at this present time.”Soriot pointed to the likes of ACE inhibitors and SGLT2 drugs as examples of the progress made in recent years to treat specific groups of cardiovascular patients.“There\'s more and more of those technologies, and we need just to pick the right products to really help patients with heart disease,” the CEO added. AstraZeneca disclosed its discontinuation of AZD3427 alongside the removal of two other new molecular entities from the pipeline. The drugmaker confirmed the removal of AZD0233, a CX3CR1 modulator that was in development as a treatment for dilated cardiomyopathy. AstraZeneca terminated a phase 1 trial of the candidate last month over an adverse finding in a nonclinical, chronic toxicology study.The company also revealed it had axed a COVID-19 vaccine program. AstraZeneca moved the mRNA viruslike particle vaccine program into phase 1 in late 2023. Recently, the company reported that a vaccine candidate was well tolerated compared to Pfizer and BioNTech’s Comirnaty and generated similar immunogenicity at one-third of the dosage.